BioCryst Pharmaceuticals(BCRX)
DURHAM, NCPharmaceutical
Focus: BioCryst is a public specialty pharmaceutical company focused on small-molecule therapeutics for rare diseases, anchored by ORLADEYO (berotralstat) for hereditary angioedema (HAE). The company operates as a late-stage biotech with commercial infrastructure in Durham, NC.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
23+3 this month
Stable — net +3 jobs in 30d
13 added, 10 removed. Backfill posture.
Recent layoff filing — 47 affected
- 8/4/2026 — Hoover, AL · 47 affected · Closure
Source: state DOL filings via Big Local News
Should You Work at BioCryst Pharmaceuticals?
AI assessmentBioCryst suits pharma professionals seeking rare-disease expertise and commercial execution experience, but requires risk tolerance for single-product dependency and potential organizational churn as pipeline matures.
Why Work Here
- Rare disease focus with an approved, revenue-generating commercial product (ORLADEYO at peak lifecycle generating $52M Part D spending) provides product-market validation and stable base funding.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
1 imminent
RAPIVAB
Hiring
Stable
Revenue
$331M
FY2025
Key Products
$52M Part DGrowing
Peak
Help build intelligence for BioCryst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.